Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 47 entries
Sorted by: Best Match Show Resources per page
Trial Watch: Anticancer radioimmunotherapy.

Oncoimmunology

Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 24319634
Oncoimmunology. 2013 Sep 01;2(9):e25595. doi: 10.4161/onci.25595. Epub 2013 Jul 03.

Radiotherapy has extensively been employed as a curative or palliative intervention against cancer throughout the last century, with a varying degree of success. For a long time, the antineoplastic activity of X- and γ-rays was entirely ascribed to their...

Cite
Vacchelli E, Vitale I, Tartour E, et al. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology. 2013;2(9):e25595doi: 10.4161/onci.25595.
Vacchelli, E., Vitale, I., Tartour, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013). Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology, 2(9), e25595. https://doi.org/10.4161/onci.25595
Vacchelli, Erika, et al. "Trial Watch: Anticancer radioimmunotherapy." Oncoimmunology vol. 2,9 (2013): e25595. doi: https://doi.org/10.4161/onci.25595
Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology. 2013 Sep 01;2(9):e25595. doi: 10.4161/onci.25595. Epub 2013 Jul 03. PMID: 24319634; PMCID: PMC3850274.
Copy Download .nbib Format: NLM
Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine.

Frontiers in oncology

Petitprez F, Sun CM, Lacroix L, Sautès-Fridman C, de Reyniès A, Fridman WH.
PMID: 30319963
Front Oncol. 2018 Sep 25;8:390. doi: 10.3389/fonc.2018.00390. eCollection 2018.

Tumors are formed by aggregates of cells of various origins including malignant, stromal and immune cells. The number of therapies targeting the microenvironment is increasing as the tumor microenvironment is more and more recognized as playing an essential role...

Cite
Petitprez F, Sun CM, Lacroix L, et al. Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Front Oncol. 2018;8:390doi: 10.3389/fonc.2018.00390.
Petitprez, F., Sun, C. M., Lacroix, L., Sautès-Fridman, C., de Reyniès, A., & Fridman, W. H. (2018). Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Frontiers in oncology, 8390. https://doi.org/10.3389/fonc.2018.00390
Petitprez, Florent, et al. "Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine." Frontiers in oncology vol. 8 (2018): 390. doi: https://doi.org/10.3389/fonc.2018.00390
Petitprez F, Sun CM, Lacroix L, Sautès-Fridman C, de Reyniès A, Fridman WH. Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Front Oncol. 2018 Sep 25;8:390. doi: 10.3389/fonc.2018.00390. eCollection 2018. PMID: 30319963; PMCID: PMC6167550.
Copy Download .nbib Format: NLM
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research

Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S.
PMID: 34407968
Clin Cancer Res. 2021 Aug 18; doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18.

PURPOSE: A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types,...

Cite
Terry S, Dalban C, Rioux-Leclercq N, et al. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-0972.
Terry, S., Dalban, C., Rioux-Leclercq, N., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., Lacroix, G., Lorens, J. B., Gausdal, G., Fridman, W. H., Mami-Chouaib, F., Chaput, N., Beuselinck, B., Chabaud, S., Barros-Monteiro, J., Vano, Y., Escudier, B., Sautès-Fridman, C., Albiges, L., & Chouaib, S. (2021). Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry, Stéphane, et al. "Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021 Aug 18; doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18. PMID: 34407968.
Copy Download .nbib Format: NLM
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Oncoimmunology

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26137404
Oncoimmunology. 2015 Mar 02;4(4):e1008866. doi: 10.1080/2162402X.2015.1008866. eCollection 2015 Apr.

The term "immunogenic cell death" (ICD) is now employed to indicate a functionally peculiar form of apoptosis that is sufficient for immunocompetent hosts to mount an adaptive immune response against dead cell-associated antigens. Several drugs have been ascribed with...

Cite
Pol J, Vacchelli E, Aranda F, et al. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4(4):e1008866doi: 10.1080/2162402X.2015.1008866.
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology, 4(4), e1008866. https://doi.org/10.1080/2162402X.2015.1008866
Pol, Jonathan, et al. "Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy." Oncoimmunology vol. 4,4 (2015): e1008866. doi: https://doi.org/10.1080/2162402X.2015.1008866
Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015 Mar 02;4(4):e1008866. doi: 10.1080/2162402X.2015.1008866. eCollection 2015 Apr. PMID: 26137404; PMCID: PMC4485780.
Copy Download .nbib Format: NLM
Trial Watch: Monoclonal antibodies in cancer therapy.

Oncoimmunology

Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G.
PMID: 22720209
Oncoimmunology. 2012 Jan 01;1(1):28-37. doi: 10.4161/onci.1.1.17938.

Since the advent of hybridoma technology, dating back to 1975, monoclonal antibodies have become an irreplaceable diagnostic and therapeutic tool for a wide array of human diseases. During the last 15 years, several monoclonal antibodies (mAbs) have been approved...

Cite
Galluzzi L, Vacchelli E, Fridman WH, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1(1):28-37doi: 10.4161/onci.1.1.17938.
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zucman-Rossi, J., Zitvogel, L., & Kroemer, G. (2012). Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology, 1(1), 28-37. https://doi.org/10.4161/onci.1.1.17938
Galluzzi, Lorenzo, et al. "Trial Watch: Monoclonal antibodies in cancer therapy." Oncoimmunology vol. 1,1 (2012): 28-37. doi: https://doi.org/10.4161/onci.1.1.17938
Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2012 Jan 01;1(1):28-37. doi: 10.4161/onci.1.1.17938. PMID: 22720209; PMCID: PMC3376976.
Copy Download .nbib Format: NLM
The European Academy of Tumor Immunology: Bridging fields, continents and generations.

Oncoimmunology

Kroemer G, Fridman WH, Sautès-Fridman C, Zitvogel L.
PMID: 22720233
Oncoimmunology. 2012 Mar 01;1(2):127-128. doi: 10.4161/onci.1.2.18796.

THE EUROPEAN ACADEMY OF TUMOR IMMUNOLOGY (EATI, OFFICIAL WEBSITE: http://eati.landesbioscience.com/index.html) has been founded in 2011 with the idea of creating a novel organization that responds to the need of structuring the European research space in this expanding, clinically ever...

Cite
Kroemer G, Fridman WH, Sautès-Fridman C, et al. The European Academy of Tumor Immunology: Bridging fields, continents and generations. Oncoimmunology. 2012;1(2):127-128doi: 10.4161/onci.1.2.18796.
Kroemer, G., Fridman, W. H., Sautès-Fridman, C., & Zitvogel, L. (2012). The European Academy of Tumor Immunology: Bridging fields, continents and generations. Oncoimmunology, 1(2), 127-128. https://doi.org/10.4161/onci.1.2.18796
Kroemer, Guido, et al. "The European Academy of Tumor Immunology: Bridging fields, continents and generations." Oncoimmunology vol. 1,2 (2012): 127-128. doi: https://doi.org/10.4161/onci.1.2.18796
Kroemer G, Fridman WH, Sautès-Fridman C, Zitvogel L. The European Academy of Tumor Immunology: Bridging fields, continents and generations. Oncoimmunology. 2012 Mar 01;1(2):127-128. doi: 10.4161/onci.1.2.18796. PMID: 22720233; PMCID: PMC3376980.
Copy Download .nbib Format: NLM
Trial watch: Dendritic cell-based interventions for cancer therapy.

Oncoimmunology

Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
PMID: 23170259
Oncoimmunology. 2012 Oct 01;1(7):1111-1134. doi: 10.4161/onci.21494.

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide repertoire of responses that span from the development of self-tolerance to the elicitation of potent cellular and humoral immunity. Accordingly, DCs are involved in the...

Cite
Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012;1(7):1111-1134doi: 10.4161/onci.21494.
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology, 1(7), 1111-1134. https://doi.org/10.4161/onci.21494
Galluzzi, Lorenzo, et al. "Trial watch: Dendritic cell-based interventions for cancer therapy." Oncoimmunology vol. 1,7 (2012): 1111-1134. doi: https://doi.org/10.4161/onci.21494
Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012 Oct 01;1(7):1111-1134. doi: 10.4161/onci.21494. PMID: 23170259; PMCID: PMC3494625.
Copy Download .nbib Format: NLM
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Oncoimmunology

Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 23243596
Oncoimmunology. 2012 Nov 01;1(8):1323-1343. doi: 10.4161/onci.22009.

Solid tumors are constituted of a variety of cellular components, including bona fide malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor stroma exerts major pro-tumorigenic and immunosuppressive functions, reflecting the capacity of...

Cite
Senovilla L, Vacchelli E, Galon J, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012;1(8):1323-1343doi: 10.4161/onci.22009.
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012). Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology, 1(8), 1323-1343. https://doi.org/10.4161/onci.22009
Senovilla, Laura, et al. "Trial watch: Prognostic and predictive value of the immune infiltrate in cancer." Oncoimmunology vol. 1,8 (2012): 1323-1343. doi: https://doi.org/10.4161/onci.22009
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012 Nov 01;1(8):1323-1343. doi: 10.4161/onci.22009. PMID: 23243596; PMCID: PMC3518505.
Copy Download .nbib Format: NLM
Trial Watch: Toll-like receptor agonists in oncological indications.

Oncoimmunology

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25083332
Oncoimmunology. 2014 Aug 01;3:e29179. doi: 10.4161/onci.29179. eCollection 2014.

Toll-like receptors (TLRs) are an evolutionarily conserved group of enzymatically inactive, single membrane-spanning proteins that recognize a wide panel of exogenous and endogenous danger signals. Besides constituting a crucial component of the innate immune response to bacterial and viral...

Cite
Aranda F, Vacchelli E, Obrist F, et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology. 2014;3:e29179doi: 10.4161/onci.29179.
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Cremer, I., Henrik Ter Meulen, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology, 3e29179. https://doi.org/10.4161/onci.29179
Aranda, Fernando, et al. "Trial Watch: Toll-like receptor agonists in oncological indications." Oncoimmunology vol. 3 (2014): e29179. doi: https://doi.org/10.4161/onci.29179
Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology. 2014 Aug 01;3:e29179. doi: 10.4161/onci.29179. eCollection 2014. PMID: 25083332; PMCID: PMC4091055.
Copy Download .nbib Format: NLM
Trial Watch-Oncolytic viruses and cancer therapy.

Oncoimmunology

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 27057469
Oncoimmunology. 2015 Dec 08;5(2):e1117740. doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb.

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to...

Cite
Pol J, Buqué A, Aranda F, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2015;5(2):e1117740doi: 10.1080/2162402X.2015.1117740.
Pol, J., Buqué, A., Aranda, F., Bloy, N., Cremer, I., Eggermont, A., Erbs, P., Fucikova, J., Galon, J., Limacher, J. M., Preville, X., Sautès-Fridman, C., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2016). Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology, 5(2), e1117740. https://doi.org/10.1080/2162402X.2015.1117740
Pol, Jonathan, et al. "Trial Watch-Oncolytic viruses and cancer therapy." Oncoimmunology vol. 5,2 (2016): e1117740. doi: https://doi.org/10.1080/2162402X.2015.1117740
Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2015 Dec 08;5(2):e1117740. doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb. PMID: 27057469; PMCID: PMC4801444.
Copy Download .nbib Format: NLM
Trial Watch: Chemotherapy with immunogenic cell death inducers.

Oncoimmunology

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 24800173
Oncoimmunology. 2014 Jan 01;3(1):e27878. doi: 10.4161/onci.27878. Epub 2014 Mar 01.

Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs, including conventional chemotherapeutics as well as targeted anticancer agents, originates (at least in part) from their ability to elicit a novel or reinstate a pre-existing tumor-specific immune response....

Cite
Vacchelli E, Aranda F, Eggermont A, et al. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014;3(1):e27878doi: 10.4161/onci.27878.
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology, 3(1), e27878. https://doi.org/10.4161/onci.27878
Vacchelli, Erika, et al. "Trial Watch: Chemotherapy with immunogenic cell death inducers." Oncoimmunology vol. 3,1 (2014): e27878. doi: https://doi.org/10.4161/onci.27878
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014 Jan 01;3(1):e27878. doi: 10.4161/onci.27878. Epub 2014 Mar 01. PMID: 24800173; PMCID: PMC4008470.
Copy Download .nbib Format: NLM
Trial Watch: Adoptive cell transfer immunotherapy.

Oncoimmunology

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
PMID: 22737606
Oncoimmunology. 2012 May 01;1(3):306-315. doi: 10.4161/onci.19549.

During the last two decades, several approaches for the activation of the immune system against cancer have been developed. These include rather unselective maneuvers such as the systemic administration of immunostimulatory agents (e.g., interleukin-2) as well as targeted interventions,...

Cite
Galluzzi L, Vacchelli E, Eggermont A, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology. 2012;1(3):306-315doi: 10.4161/onci.19549.
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology, 1(3), 306-315. https://doi.org/10.4161/onci.19549
Galluzzi, Lorenzo, et al. "Trial Watch: Adoptive cell transfer immunotherapy." Oncoimmunology vol. 1,3 (2012): 306-315. doi: https://doi.org/10.4161/onci.19549
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology. 2012 May 01;1(3):306-315. doi: 10.4161/onci.19549. PMID: 22737606; PMCID: PMC3382856.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 47 entries